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Interest surrounding the role that skin microbes play in various aspects of human health has 
recently experienced a timely surge, particularly among researchers, clinicians, and 
consumer-focused industries. The world is now approaching a post-antibiotic era where 
conventional antibacterial therapeutics have shown a loss in effectiveness due to overuse, 
leading to the looming antibiotic resistance crisis. The increasing threat posed by antibiotic 















resulted in global interest for alternative solutions. Recent studies have demonstrated that 
imbalances in skin microbiota are associated with assorted skin diseases and infections. 
Specifically, restoration of this ecosystem imbalance results in an alleviation of symptoms, 
achieved simply by applying bacteria normally found in abundance on healthy skin to the 
skin of those deficient in beneficial bacteria. The aim of this review is to discuss the currently 
available literature on biological tools that have the potential to manipulate the skin 
microbiota, with particular focus on bacteriocins, phage therapy, antibiotics, probiotics, and 
targets of the gut-skin axis. This review will also address how the skin microbiota protects 
humans from invading pathogens in the external environment while discussing novel 
strategies to manipulate the skin microbiota to avoid and/or treat various disease states. 
Keywords: skin microbiota, bacteriocin, phage, probiotics, gut-skin axis 
 
Introduction 
The first line of defence against the outside world for humans is their skin, the largest organ 
of the body comprising 12-15% of total body weight with a surface area of 2m
2
. However, 
much like the human small intestine possessing villi that increase available surface area, the 
skin also includes discrepant features that make such calculations difficult. Furthermore, 
studies also show that the skin microbiota extends into the dermis, challenging the notion that 
deeper layers of the skin are protected from bacteria (Lange-Asschenfeldt et al. 2011; 
Nakatsuji et al. 2013). It has therefore been proposed that the average surface area of 




, to include approximately 5 
million appendages (such as sweat ducts and hair follicles). 
The skin is composed of two layers: the epidermis and the dermis. The epidermis is the skin‘s 















Malpighian layers. The cornified layer is the body‘s first barrier to the external environment, 
predominantly composed of dead cells. Keratinocytes are located in the granular layer, while 
melanocytes reside in the Malpighian layer. Below the epidermis is the dermis layer, rich in 
collagen and elastin, giving skin strength and elasticity. The dermis layer is comprised of 
sebaceous glands, hair follicles, nerves, capillaries and blood vessels (Yousef and Sharma 
2018). 
Unlike the ‗jungle‘ of the gastrointestinal (GI) tract, the ecology of skin is predominantly 
akin to a desert-dry, vast and lacking nutrients. While the exact composition of the skin 
microbiota in healthy individuals is still unknown, we imagine, similar to the gut, that the 
microbial composition is quite individualistic and is dependent on many factors such as sex, 
hygiene, delivery mode, cohabitation, and geography (Cuscó et al., 2017; Lunjani et al., 
2019). The skin exhibits widely varying pH and temperature profiles across its surface, and, 
while some regions are relatively densely populated, only certain bacterial phyla colonise: 
Proteobacteria, Firmicutes, Bacteroidetes and Actinobacteria, with the latter being the most 
diverse and prevalent phylum in healthy skin (Gao et al. 2008). Key human skin bacterial 
residents include Staphylococcus, Corynebacterium, Cutibacterium (formally known as 
"Propionibacterium", (Scholz and Kilian 2016)), Micrococcus, Streptococcus, 
Brevibacterium, Acinetobacter, and Pseudomonas (Rosenthal et al. 2011). Microbial 
composition is dependent on optimum growth conditions and phenotypic preferences, 
different microbes reside in various areas of the skin. For example, Cutibacterium species 
dominate lipophilic areas such as the back, while Staphylococcus and Corynebacterium 
appear to be the dominant populations in moist areas such as the inguinal crease or toe 
webspace area, and Gram-negative microbes populate dry areas like the volar forearm (Grice 















While in recent years it was suggested that an overabundance of certain bacterial genera was 
the root cause of particular skin disorders (for example, a surge in Cutibacterium acnes (C. 
acnes) results in the development of acne vulgaris), it is now generally recognised that the 
disequilibrium between larger microbial communities might be one additional and important 
factor behind the pathogenesis of selected skin diseases (Fitz-Gibbon et al. 2014). 
Furthermore, evidence of the link between gut and skin microbiomes is growing, with many 
studies demonstrating how the GI ecosystem acts as a major regulator of the gut-skin axis 
(Arck et al. 2010; O‘Neill et al. 2016; Vaughn, Notay and Clark 2017; Salem et al. 2018). 
The looming threat of antibiotic resistance has increased awareness to the need for alternative 
antimicrobial therapies, thus it is imperative to have a clear understanding of the mechanisms 
of action. This review presents current and novel treatment strategies for various skin 
diseases, to generate a greater comprehension of how different therapeutic interventions can 
manipulate the skin microbiota.  
 
Microbiota imbalances associated with skin diseases and an overview of current, 
existing and conventional treatments 
Here we review what is known of the role of microbes in the pathogenesis of skin diseases 
and some of the therapies either currently in use or under development to ameliorate some of 
these skin pathologies, see table 1. 
 
Impetigo 
 Impetigo is a common skin infection particularly in children, linked to a surge of either 















cause is an overabundance of Staphylococcus aureus which produces toxins, such as 
exfoliative toxins A and B, that disrupt epidermal cells, resulting in blister formation. There 
are 2 types of impetigo: bullous (blister-shiny lesions) and non-bullous (crusted lesions), the 
latter being most common (70% of impetigo cases), (Pereira 2014). Current treatments 
include both systemic and topical antibiotics, the latter is more favourable where fusidic acid 
and Mupirocin are commonly used. Systemic treatments include a variety of macrolide 
antibiotics such as erythromycin (Hartman-Adams, Banvard and Juckett 2014). A new topical 
biological treatment for impetigo is Ozenoxacin, a novel quinolone antibiotic that targets S. 
aureus and Staphylococcus pyogenes. Ozenoxacin inhibits DNA replication by targeting 
DNA gyrase A and topoisomerase IV (Sahu and Mishra 2018). 
 
Atopic dermatitis (AD) 
AD is an inflammatory skin condition characterised by red, itchy and eczematous lesions (dry 
skin patches). It can be both chronic and recurrent and affects children primarily. AD 
pathogenesis is associated to an imbalance of coagulase negative staphylococci that results in 
a surge of S. aureus as well as a reduction in other skin commensals such as Streptococcus, 
Cutibacterium, Prevotella, Acinetobacter, Corynebacterium species (Dekio et al. 2007; Kong 
et al. 2012; Bjerre et al. 2017; Sun et al. 2019). 
There are numerous treatments used currently to treat AD and these include topical 
corticosteroids (main treatment), antiseptic treatments: octenidine and chlorhexidine, and 
topical antibiotics: mupirocin, fusidic acid and retapamulin (Nowicki et al. 2015). The effect 
of a topical lotion was demonstrated by Blanchet-Réthoré et al., (2017). By topically 
applying a lotion containing a heat-treated strain of Lactobacillus johnsonii (NCC 533) to the 















was heat-treated to ensure that the beneficial Lb. johnsonii did not replicate. Other novel 
treatments are discussed later in this review. 
 
Acne vulgaris  
Cutibacterium acnes is an anaerobic skin commensal associated with the pathogenesis of the 
skin disease acne vulgaris more commonly known as acne (Liu et al., 2015). Contrary to 
previous reports that increased abundance of C. acnes was the driving force behind acne 
vulgaris, it is now recognised that C. acnes is the most dominant bacterial species within the 
pilosebaceous follicle for both acne and non-acne sufferers. Bek-Thomsen et al., (2008) 
compared the microbial diversity of follicles of acne patients to healthy individuals using 16S 
rRNA genes (n=8). C. acnes was discovered in the follicles of both groups while S. 
epidermidis and low amounts of other species were also present in acne patients. It is now 
thought that a loss of diversity of skin microbiota coupled with initiation of innate immunity 
is linked to the pathogenesis of this inflammatory condition (Barnard et al. 2016; Szabó et al. 
2017; Dréno et al. 2018).  
Certain C. acnes strains namely type1A, are linked to both the progression of acne and the 
increased severity of lesions and scars in acne patients (Fitz-Gibbon et al., 2014; Pécastaings 
et al., 2018). Current treatments of acne vulgaris have been extensively reviewed by Rathi, 
2011; in brief, they include topical benzoyl peroxide or salicylic acid, topical antibiotics: 
clindamycin, or oral antibiotics: erythromycin and tetracyclines, topical retinoids (vitamin A 
derivatives) and oral retinoids: isotretinoin (more commonly known as Roaccutane). Myrtus 
communis is a species of myrtle plant common to the Mediterranean region; from its leaves 
an isopropyl acetate extract Myrtacine® is prepared. Feuillolay et al., 2016 demonstrated that 















C. acnes in antibiotic resistant states. Antibiotic potency improved when in combination with 
Myrtacine®. Pécastaings et al., 2018 showed in vivo that a Myrtacine® based cream lowered 




Psoriasis is a skin inflammatory autoimmune disease, characterised by dry, red, itchy, scaling 
patches on the skin, predominantly evident on the face and trunk of the body. Skin microbiota 
namely Corynebacterium, Cutibacterium, Staphylococcus, and Streptococcus species may 
contribute to the pathogenesis of chronic plaque psoriasis. Gao et al., (2008) reported a 
‗substantial alteration‘ in skin microbial composition (n=6) from swabs, when using 16S 
rRNA genes to assess the skin microbiota in healthy and psoriatic skin. Firmicutes were 
observed at higher levels, while Actinobacteria and Cutibacterium exhibited decreased 
abundance in psoriatic skin when compared to healthy persons, Alekseyenko et al., (2013) 
reported similar results. However, Fahlen et al., (2012) employed skin biopsies (n=22) and 
found no difference in levels of Firmicutes or Actinobacteria between healthy and psoriatic 
skin, but observed significantly higher levels of Proteobacteria in psoriatic skin on the trunks 
of patients when compared to healthy subjects. The role skin microbiota play in the 
pathogenesis of psoriasis remains unclear (Benhadou et al. 2018). Current treatments include 
topical corticosteroids (most frequently prescribed), anthralin, derived from goa powder from 
the araroba tree (which functions in slowing growth of skin cells), vitamin D analogues, 
topical retinoids, and coal-tar among others. Novel treatments are immunotherapy focused; 
for example interleukin antagonists and inhibitors, adenosine receptor agonists, tumour 


















Rosacea is an inflammatory skin disease that is characterised by redness, flushing, pimples, 
pustules, dilated blood vessels and thickening of the skin (Mikkelsen et al. 2016). It is linked 
to immune dysfunction and neurovascular dysregulation. There are 4 major subtypes of 
rosacea erythematotelangiectatic, papulopustular, phymatous, and ocular. Current treatments 
target inflammatory pathways involved in the pathogenesis of rosacea and are predominately 
topical including metronidazole, azelaic acid, ivermectin, and brimonidine tartrate, 
oxymetazoline hydrochloride with doxycycline the only approved oral drug (Rainer, Kang 
and Chien 2017; Engin et al. 2020). Recently a study by Rainer et al., (2020) (n=38: 19 
healthy, 19 rosacea) showed that the skin microbiota of individuals with rosacea appear to 
have greater abundance of Corynebacterium kroppenstedtii, Campylobacter ureolyticus and 
Prevotella intermedia and decreased levels of Roseomonas mucosa when compared to 
healthy subjects. 
 
Cutaneous leishmaniasis  
A vector borne tropical parasitic disease called cutaneous leishmaniasis (CL) is a growing 
problem especially in developing countries, with 12 million cases globally and 1.5 million 
new cases diagnosed every year. CL is transmitted by the female sand-fly and presents on the 
skin as an erythematous papule that develops into an ulcer with a raised and distinct border 
(Markle and Makhoul 2004). In mice this disease induces dysbiosis within the skin 
microbiota (a surge in abundance of Staphylococcus and Streptococcus species) resulting in 
inflammation (Gimblet et al. 2017). Amphotericin B, an antibiotic originally isolated from 















at eliminating these ulcers  (Mushtaq, Dogra and Dogra 2016). No studies investigating the 
restoration of skin microbiota has been documented as of yet, however, as skin appears 
normal after treatment and due to general mode of action of amphotericin B binding to 
ergosterol damaging cell membrane integrity, one can speculate that the healthy microbiota is 
also restored. 
 
Skin cancer  
Information regarding the microbiota of skin melanoma is scarce however a recent study by 
Mrázek et al., (2019) found that the microbial diversity of healthy and melanoma pig skin 
tissue were significantly different, whereby melanoma samples showed increased levels of 
Fusobacterium and Trueperella genera. Further characterisation is required to explore the 
link of these microbial differences with melanoma and skin cancer and to detect if a skin 
microbe could be employed as a biomarker for melanoma. 
 
Fungal skin infections 
Fungi appear to play a functional role in the skin microbiome, albeit that their exact role is 
not fully understood (Findley et al. 2013). Malassezia is the most abundant genus of fungi 
present on human skin and is present across different body sites. Malassezia is an 
opportunistic pathogen and is linked both directly and indirectly via immune system to many 
skin conditions including dandruff, atopic eczema/dermatitis, pityriasis versicolor, seborrheic 
dermatitis, and folliculitis (Underhill and Iliev 2014; Limon, Skalski and Underhill 2017). It 















Current broad spectrum anti-fungal treatments for numerous fungal skin infections such as 
‗dermatophytosis of the foot‘ (athletes foot), candida and ringworm include clotrimazole, 
miconazole, econazole, ketoconazole, naftifine, terbinafine, and Amphotericin B (Bell 2007; 
Hay 2018). 
Some non-antibiotic methods to influence the skin mycobiota include zinc pyrithione (ZPT), 
synthesised from the antimicrobial metabolite aspergillic acid, that displays a broad spectrum 
of activity inhibiting fungi, Gram-positive and -negative bacteria (Schwartz 2016). The exact 
mode of action of ZPT is not fully understood but it is thought to inhibit mitochondrial 
function, amplify levels of cellular zinc and reduce expression of lipases. ZPT is commonly 
used  in anti-dandruff shampoos (Saunders, Scheynius and Heitman 2012; Park et al. 2018). 
Liposomes, niosomes, ethosomes, microemulsions, nanoparticles, microspheres and micelles 
have all been proposed as novel delivery agents for anti-fungal skin treatments. Use of such 
novel interventions results in enhanced bioavailability, reduced side effects, and deeper 
diffusion of anti-fungal drugs into the skin (Kumar et al., 2014). In a clinical trial of duration 
56 days involving 60 males with moderate to severe dandruff, Reygagne et al., (2017) found 
that intake of the oral probiotic Lactobacillus paracasei NCC2461 ST11 significantly 
lessened the severity of dandruff, potentially by influencing the skin barrier and immune 
system. This study again highlights the gut-skin connection, whereby treating the gut results 
in benefit to the skin microbiome. The precise role mycobiota play in modulating skin 
disorders remains to be fully comprehended. 
 
The Gut–skin-brain connection 
The hypothesis of a gut-skin-brain connection was first put forward in the 1930s by Stokes 















existed, see figure 2. These early researchers postulated that brain emotions such as stress and 
depression impact the gut, altering the overall microbial composition which in turn increases 
the permeability of the intestines and thereby leads to the pathogenesis of skin diseases like 
‗erythema, urticaria and dermatitis‘ (Stokes and Pillsbury 1930). In 1981 another link of the 
gut-skin-brain axis was reported whereby ‗peptide-containing cells in skin, brain and gut‘ 
arise from a common embryonic origin- dopaminergic precursors (Teitelman, Joh and Reis 
1981). Arck et al., (2010) reviews the existence of a gut-brain-skin axis and presents the gut 
as the origin of many skin diseases, see figure 2. Arck et al., also report that the ingestion of 
probiotics in mice beneficially affected the skin microbiota by reducing skin inflammation, 
restoring homeostasis, improving hair growth and stress responses in tissues, 
Additionally, the brain-gut and gut-brain connections are also well established and more 
recently it has become widely accepted that the interactions are bi-directional. For example, 
Parkinson‘s disease (PD) was originally described as a ‗shaking palsy‘ in 1817 and thought to 
be a disease that began in the brain and spread throughout the body. However, it was also 
noted at that time that by treating GI complaints such as constipation, the motor function of 
patients improved. Now ground-breaking research using animal models is demonstrating that 
injections of alpha-synuclein (prion involved in the pathogenesis of PD) into the gut induces 
PD related brain pathology and symptoms, indicating that the gut-brain connection is indeed 
bi-directional (Martin et al. 2018; Uemura et al. 2018; O‘Donovan et al. 2019). This supports 
the hypothesis that the skin-gut connection may be also bi-directional and that many skin 
diseases also may begin in the gut. 
Hill et al., 2017 reported that the mode of delivery of infants can shape the composition of 
their gut microbiota. In comparison to babies born via the birth canal (whose gut microbiota 
remains relatively stable over the first six months), the initial microbiota of babies born via 















their faecal material. Differences between natural and caesarean delivery can still be observed 
at 24 weeks, however, variances diminish over time. Specifically, the microbial composition 
of the babies‘ gut depends on which microbes first colonise the skin (Rodríguez et al. 2015). 
This suggests the presence of a skin- gut axis and opens the door for many mechanistic 
questions: Can coating our skin with topical probiotics have an impact on the microbial 
composition of the gut? Does the brain transmit signals to the gut which in turn 
communicates to the skin, or are these signals initiated in the gut? 
The skin and brain are connected through the hypothalamic-pituitary-adrenal (HPA) axis 
which links stress effects to the skin (Arck et al. 2006; Chen and Lyga 2014). Both 
psychological and environmental stress stimulate secretion of stress hormones along the HPA 
axis, such as corticotropin-releasing hormone (CRH). Binding of CRH to its receptor initiates 
a cascade of events, one such example being the secretion of adrenocorticotropic hormone 
(ACTH) which in turn stimulates the release of glucocorticoids such as cortisol, (the primary 
stress hormone), from the adrenal cortex. Interestingly, both CRH and ACTH are produced in 
skin cells thereby establishing the skins own peripheral HPA axis (Kim et al. 2013). Prolactin 
(PRL) is released from the brain which in turn stimulates sebum production and keratinocyte 
proliferation. In the skin, prolactin is thought to modulate epithelial cell growth through a 
number of pathways including altering cytokine release in the skin and through prolactin‘s 
ability to bind specific skin receptors (Paus 1991). Calcitonin gene-related peptide and 
substance P are upregulated in the dorsal root ganglia, thus inducing an immune response 
triggering production of inflammatory cytokines and activation of mast cells, resulting in 
neurogenic inflammation in the skin. There is now a strong brain-skin connection that can 

















Small intestinal barrier overgrowth (SIBO) 
SIBO is defined as ‗an increase in the relative abundance and/or alteration in the type of 
bacteria in the upper gastrointestinal tract‘ (Bures et al. 2010). Interest surrounding intestinal 
permeability is growing, as scientists continue to uncover links to several human diseases 
such as autoimmune disease (Visser et al. 2009), liver disease (Cariello et al. 2010) and acne 
vulgaris (Bowe and Logan 2011) to name a few. This paragraph focuses on how intestinal 
permeability manifests itself in skin diseases and how such maladies can be alleviated. It was 
hypothesised by Stokes and Pillsbury in 1930, and has since been reported by Salem et al., 
2018, that hypochlorhydria (low production of stomach acid) leads to the presence of colonic 
bacteria in the small intestine, resulting in inflammation and dysbiosis i.e. SIBO. O‘Neill et 
al., 2016 eloquently illustrated mechanisms for different pathways potentially involved in the 
gut-skin axis in relation to SIBO and proposed how metabolites (either generated from 
microbial metabolism or consumed from one‘s diet) reach the skin and result in pathological 
changes. The same researchers also reviewed current literature to determine how allergies to 
foods like peanuts are more likely to occur when the skin is exposed to peanuts before the 
gut, while also discussing the degree to which high-fat western diets can lead to 
overstimulation of lipid production in sebaceous glands of hair follicles via the mTor-FoxO1 
pathway.  
Colonic bacteria are associated with the production of short-chain fatty acids (SCFAs) such 
as propionic acid and butyric acid. In the colon, colonocytes are present which absorb 95% of 
SCFAs (Gougerot and Peyre 1936; Wong et al. 2006). However, colonic bacteria can also be 
found in the small intestine (Salem et al. 2018) and we hypothesise that this may contribute 















responsible for motor function of the large intestine, however only recently has the pattern of 
neuronal activity of the ENS, that generates contractions in the smooth muscle of the GI, 
been identified (Spencer et al. 2018). This study demonstrated that the gut could produce its 
own neuronal pattern and can function independently to the brain, like a ―second brain.‖ Is 
the gut our communication station or the central processing unit of our bodies? Further 
investigations into the gut‘s mechanisms of communication with the skin and other organs of 
the body are clearly warranted. While much work is required to identify such mechanisms of 
communication and determine how experimental outcomes can be manipulated to alleviate 
actual human disease symptoms,  it remains clear that there is immense potential for further 
research into the gut-skin axis. Stokes and Pillsbury were indeed well ahead of their time. 
 
Biological tools to treat skin diseases- direct 
Table 2 summarises the following biological tools that are used or have potential to modulate 
the skin microbiota as is also depicted in figure 1. 
 
Antimicrobial peptides (AMPs) 
AMPs are small polypeptide molecules (<10kDa), produced by our skin cells and skin 
microbiota and are part of the innate immune system. As their name suggests, AMPs are 
antimicrobial by nature but also function by modulating immune responses. The amphipathic 
nature and positive charge of AMPs aids in their role in disrupting the negatively charged 
phospholipid membrane of target cells (Hancock and Sahl 2006). Takahashi and Gallo, 2017 
recently reported that there are at least 20 AMPs produced by our skin and skin bacteria; with 
keratinocytes as the main producers and cathelicidins and defensins being the two major 















of the epidermal layer of skin is a common result of skin disorders. AMP production is 
downregulated in skin diseases like atopic dermatitis (AD) resulting in a surge in S. aureus 
but upregulated in psoriasis and rosacea where it results in inflammation (Pfalzgraff, 
Brandenburg and Weindl 2018), this could be a plausible reason as to why AD sufferers are 
more susceptible to skin infection than patients with psoriasis (Marcinkiewicz and Majewski 
2016).  Defensins display a broad range inhibition spectrum being antimicrobial, antifungal 
and antiviral by nature. 
Defensins and cathelicidins both have an overall net positive charge enabling them to bind to 
the negatively charged membranes of bacteria and permeabilise the cells. They work 
synergistically: defensins modulate receptors on immunocompetent cells inhibiting viruses 
from binding and infecting such cells while cathelicidins are expressed in response to 
inflammatory stimulus. For example, cathelcidin LL-37 signals the migration of mast cells, 
neutrophils, monocytes and T cells to sites of inflammation, modulates immune responses 
and is involved in wound healing (Korting et al. 2012). While many reviews describe the 
mechanisms of action of various AMPs and studies of novel AMPs as potential therapeutics 
in skin diseases, few have made it past clinical trials or reached the marketplace due to 
production cost, efficacy and their potential cytotoxicity (Steinstraesser et al. 2008; Brogden 
and Brogden 2011; Kang et al. 2017). For example, omiganan, a cationic AMP, is being 
investigated as a novel therapeutic in the treatment of acne and rosacea and has passed stage 
III of clinical trials, while pexiganan a novel treatment of foot ulcers in patients with diabetes 

















Bacteriocins, a type of AMP, are small, ribosomally synthesised peptides that are heat stable, 
produced by bacteria to kill their competitors (Cotter, Ross and Hill 2012). Interest 
surrounding the therapeutic potential of bacteriocins is increasing (Behrens et al. 2017). 
Bacteriocins have an associated probiotic potential: they help bacterial colonisers become 
established in a particular environment; they can inhibit competitors or pathogens, alter the 
skin microbiota and communicate with the immune system (Dobson et al. 2012). Gillor, 
Etzion and Riley, (2008) suggested that bacteriocins have both anti- and probiotic properties. 
The first bacteriocin discovered was colicin by Gratia in 1925, when he observed that E. coli 
strains slowed/inhibited the growth of surrounding bacteria. Soon after in 1928, Rogers found 
that some Lactococcus lactis strains had inhibitory ability against Lactobacillus bulgaricus; 
this antimicrobial Nisin has since become the most characterised and well-known bacteriocin. 
Nisin is a food preservative that was approved by the FDA in 1988 and since has many 
applications (van Kraaij et al. 1999; Cheigh and Pyun 2005; Shin et al. 2016). The main 
mode of action of bacteriocins is to disrupt the cell membrane of the target organism to cause 
cell death. For example, the N- terminus region of Nisin attaches to target cell membrane and 
forms a complex with lipid II, a fundamental component in cell wall synthesis, that disrupts 
the membrane allowing the C-terminus end of nisin to enter the target cell causing cell 
permeabilisation and death (Healy et al. 2013). Bacteriocins are divided into 3 classes, which 
are further subdivided into groups based on their structures (Cotter, Hill and Ross 2005; van 
der Donk and Nair 2014; Yang et al. 2014). Class II bacteriocins are a broad group that 
unlike class I, do not undergo posttranslational changes, while class III consists of 
bacteriolysins which are large proteins that function in lysing target bacteria by inducing cell 
wall hydrolysis (Cotter, Hill and Ross 2005; Sang and Blecha 2008). Given their potential for 















bacteriocins. For this review we will focus predominantly on bacteriocins produced by skin 




Lantibiotics are Class I bacteriocins which consist of post-translationally modified peptides 
that contain some unusual amino acids namely 2,3-didehydroalanine (Dha) and 2,3- 
dehydrobutyrine (Dhb) – dehydrated derivatives of serine and threonine, respectively. Class I 
bacteriocins also contain the lanthionine residues, Lan and MeLan formed as a result of a 
reaction between cysteine with either Dha or Dhb, respectively. This results in the formation 
of Lan or MeLan bridges and gives lantibiotics their polycyclic structure (McAuliffe, Ross 
and Hill 2001). Lantibiotics (lantithione-containing antibiotic) are subdivided into 2 groups 
type A and B. Type A are cationic peptides of length ~34 amino acids and function by 
disrupting membrane integrity, while type B are globular shaped consisting of ~19 amino 
acids and function by inhibiting cell wall biosynthesis. Nisin, a lantibiotic, is a class Ia 
bacteriocin and as a result of its success, lantibiotics are of particular interest. A number of 
lantibiotics have been isolated from staphylococcal human commensals including epidermin, 
hominicin and gallidermin, that exhibit inhibitory activity on bacteria associated with skin 
dysbiosis (Götz et al. 2014).  
Originally isolated from chickens and pheasants, gallidermin is produced by S. gallinarum, 
and, while the bacterium is widespread in nature it is also present in healthy human saliva 
(Shi et al. 2015). Kellner et al., (1988) demonstrated the inhibitory activity of S. gallinarum 
(F16/ P57) Tu3928, against Cutibacterium species, key players in the pathogenesis of acne. 















undergo post-translational modifications (Götz et al. 2014). Gallidermin and epidermin have 
displayed inhibitory activity against C. acnes as well as a number of Staphylococcus and 
Streptococcus species (Kellner et al. 1988; Bonelli et al. 2006), and while S. gallinarum and 
S. epidermidis are recognised skin commensals they can also be cutaneous pathogens 
(Shields, Tschetter and Wanat 2016). Coagulase-negative staphylococci (CoNS) are regarded 
as normal skin commensals, however more and more studies are highlighting them as the root 
cause of skin and soft tissue infections, due to their ‗opportunistic pathogenic‘ nature, (Davis 
et al. 2013). 
The probiotic potential of S. hominis  (women‘s vaginal isolates MBBL 2-9) against S. 
aureus was reported by Sung et al., 2010. They described the S. hominis strain as tolerant to 
acid, resistant to bile and capable of adhering to an epithelial cell line; all of which are 
considered important probiotic properties. They found the strain also produced a bacteriocin.  
Further characterisation of this bacteriocin was carried out by Kim et al., 2010, where they 
described a novel antimicrobial peptide named ‗hominicin‘. Hominicin displayed inhibition 
against S. aureus, Methicillin-Resistant Staphylococcus aureus (MRSA) and VISA 
(vancomycin-intermediate S. aureus), and contained uncommon amino acids, similar to those 
found in Class I bacteriocins. 
Nukacin ISK-1 is a bacteriocin produced by S. warneri, originally isolated from a nukadoko 
(a fermented rice bran bed, used for the nukazuke method of pickling vegetables) (Kimura et 
al. 1997). Nukacin ISK-1 was further characterised as a broad spectrum type (II-A) 
lantibiotic with the ability of inhibiting some Staphylococcus species (Sashihara et al. 2000). 
Janek et al., 2016 discovered a S. epidermidis strain that produced a nukacin like variant 
(normally produced by S. warneri), residing on a plasmid within the S. epidermidis genome 
and also noted that a S. hominis strain (KQU-131), isolated from Thai fermented marine fish 















Staphylococcus strains exchange diverse bacteriocin genes on a frequent basis. Nukacin ISK-
1 is a broad spectrum lantibiotic with reported inhibitory capabilities against Bacillus, 
Listeria, Lactococcus, Micrococcus, Lactobacillus and Enterococcus species (Asaduzzaman 
et al. 2009). 
L. salivarius is a well-documented and characterised probiotic strain (Ocaña, Pesce de Ruiz 
Holgado and Nader-Macías 1999; Stern et al. 2006; O‘Shea et al. 2011; Messaoudi et al. 
2013), with both in vitro and in vivo studies demonstrating the bacteriocin capabilities of  
certain L. salivarius strains. Deidda et al., 2018 reported that Lactobacillus salivarius LS03, a 
probiotic strain, exhibited specific antimicrobial activity and anti-inflammatory activity 
targeted at Il-8.  They demonstrated, via the disc diffusion method, that L. salivarius LS03 
inhibited growth of C. acnes. While Corr et al., 2007 showed that the bacteriocin produced 
by L. salivarius UCC118 (Abp118) prevented harm to mice infected with Listeria 
monocytogenes (serious food borne pathogen) by comparing it to a mutant of the same strain 
unable to produce  Abp118.  
 
Other bacteriocins 
Cebrián et al., (2018) found that bacteriocin AS-48, produced by Enterococcus species, 
displayed inhibitory activity against C. acnes. Improvement in inhibition was noted when this 
bacteriocin was combined with lysozyme, a natural antimicrobial found throughout the 
animal kingdom in bodily fluids, including tears, saliva, sweat and blood  (Ragland and Criss 
2017).  Cebrián et al., (2018) further demonstrated that a combination of bacteriocin AS-48 
and lysozyme was not cytotoxic suggesting it might be a good alternative antimicrobial 















Oh et al., 2006  demonstrated Lactococcus sp. HY 449 produces a bacteriocin that displayed 
inhibitory effects on bacteria involved in skin inflammation including Staphylococcus 
epidermidis, S. aureus, C. acnes and Streptococcus pyogenes. A human patch test carried out 
on healthy female volunteers, (n=30), confirmed this bacteriocin did not irritate the patients‘ 
skin, rendering it a suitable antimicrobial for addition to cosmetic products. 
 Nakatsuji et al., 2017 demonstrated that development of a personalised probiotic cream 
could alleviate the symptoms of Atopic Dermatitis (AD) more commonly referred to as 
eczema. In AD, imbalances in the skin microbiota occur; there are deficiencies of certain skin 
bacteria such as CoNS and increases in other bacteria, such as a surge in S. aureus. They 
reported that human commensal Staphylococcus species produce AMPs which naturally 
protect against the skin pathogen S. aureus, a key player in atopic dermatitis (AD). In this 
study antimicrobial producing CoNS, that were abundant on healthy individuals and not on 
AD patients, namely S. epidermidis and S. hominis, were added to a skin cream ‗Cetaphil 
lotion‘ and introduced onto the skin of 5 AD patients in an in vivo study. Application of the 
‘antimicrobial lotion‘ to the affected body area resulted in a significant decrease in the 
numbers of S. aureus when compared to control subjects. They demonstrated that the 
inhibitory activity of the S. hominis strains applied was specific to S. aureus, including an 
MRSA strain, and did not inhibit other bacteria commonly present on human skin namely S. 
epidermidis, C. acnes, and Corynebacterium minutissimum. This study shows imbalances 
within the skin microbiota can lead to pathogenesis of skin diseases and demonstrates that 
skin commensal bacteria can alleviate the symptoms and restoring this imbalance. 
A recent study by our group, O‘Sullivan et al., (2019), demonstrates the antimicrobial power 
of staphylococci isolated from different areas of human skin on human pathogens. Certain 
CoNS produced putative novel bacteriocins that exhibited inhibitory effects against potential 
















Phenol soluble modulins (PSM) 
PSM, another type of AMP, is a group of peptides produced by microbiota that have several 
roles in pathogenesis including blood cell lysis and inflammation. PSMs also aid in the 
growth and spread of staphylococci on the skin, as well as contributing to their virulence 
(Cheung et al. 2014). Despite their virulence, antimicrobial ability of some PSMs has been 
reported. Cogen et al., 2010 and Cogen, Yamasaki, Muto, et al., 2010 observed that PSMs 
namely, PSMγ and PSMδ produced by human skin commensal S. epidermidis exhibited 
similar properties to AMPs; functioning in cell membrane disruption resulting in cell death. 
PSMγ and PSMδ inhibited skin pathogen S. aureus and also protected against group A 
streptococci. Given that the PSMs can inhibit other microbes without inhibiting the producing 
organism, it could be that PSMs give S. epidermidis a competitive advantage demonstrating 
the beneficial association of a skin commensal with skin epithelia. 
 
Short-chain fatty acids (SCFA) 
The association of increased abundance of C. acnes and C. granulosum with healthy skin has 
led to the proposition of their probiotic potential (Barnard et al. 2016). Fermentation of 
carbohydrates by bacteria results in the production of SCFAs (den Besten et al. 2013). SCFA 
impacts skin pH by increasing acidity thus protecting against pathogens. While C. acnes is a 
skin pathogen that has been associated with a number of skin conditions, it can also have 
beneficial effects. For example, Shu et al., 2013 demonstrated the antimicrobial potential of 
C. acnes in its ability to inhibit the growth of a dominant MRSA strain (USA300), both in 
vitro and in vivo in a mouse skin model by fermenting glycerol, (a carbon source that is also a 















al., 2014 demonstrated fermentation of glycerol by skin commensals- predominantly S. 
epidermidis, resulted in the production of succinic acid which suppressed  the growth of C. 
acnes on a mouse skin model. 
 
Phage therapy 
Phage therapy is another alternative therapy to antibiotics and a number of research centres 
now focus on  the development and delivery of phage therapy 
(www.phagetherapycenter.com; www.iitd.pan.wroc.pl/en/OTF/). While bacteria can also 
become resistant to phage, it is comparably easier to isolate a new phage than develop a new 
antibiotic. Though a comprehensive understanding of the effect of  phage therapy on the skin 
microbiota remains to be derived (Schommer and Gallo 2013), there is currently an 
increasing interest surrounding phage treatment as a therapeutic option. 
Phage: mode of action 
A bacteriophage (phage) is a virus that infects bacteria. Phages can replicate via the lytic or 
lysogenic cycle; both types of  phage attach to the host bacterial cell and injects its DNA into 
the cell. During lytic infection, the phage hijacks the host machinery for its own replication 
and assembly of phage particles which is followed by cell lysis and release of progeny 
phages. During the lysogenic cycle, phage DNA integrates into the host DNA and thus 
replicates in accordance with the host and is referred to as a prophage. When conditions are 
suitable the cycle switches to the lytic cycle (Sulakvelidze, Alavidze and Morris  Jr 2001). 
Phage therapy generally exploits exclusively lytic phage. Hence phage, normally with a 
narrow host range, can reduce the number of bacteria in the environment and so can impact 
















Abedon et al., 2011 have carried out an extensive review of the history of phage treatment in 
human infections including skin infections particularly of ulcers and wound healing. Here we 
will focus on current phage therapy with mention of some past phage therapy in treatment of 
bacterial skin infections. In 1936 Gougerot and Peyre demonstrated the positive outcome of 
phage therapy on different skin infections, particularly furunculosis, more commonly known 
as ‗boils‘, an infection of the hair follicle resulting in abscess and pus formation (Ibler and 
Kromann 2014). The treatment which proved most successful, (which was repeated every 48 
hours for a total of 8-10 applications), involved opening the skin pustules with a syringe 
containing phage followed by direct application of the phage to the area, and the dressing 
applied also contained phage (Gougerot and Peyre 1936). They also proposed a similar 
method of phage therapy in the treatment of bacterial skin diseases like impetigo, a 
staphylococcal or streptococcal skin infection that presents in the form of red crust-like sores 
(Hartman-Adams, Banvard and Juckett 2014). Another early documented effective use of 
phage therapy in the treatment of ‗suppurative skin infections‘ was reported by Cislo et al., 
1987. Here they carried out a 16-week study on 31 patients with skin infections caused by 
‗Pseudomonas, Staphylococcus, Klebsiella, Proteus and Escherichia species. In 25 of the 31 
cases, improvement on a scale from ‗outstanding‘ to ‗transitory‘ was reported with the former 
being a much higher number (16/31 cases). The phage therapy reduced inflammation, 
increased healing of wounds and ulcers and inhibited the bacteria in question. 
Pyophage is a cocktail of phage targeting Staphylococcus, Streptococcus, Pseudomonas, 
Proteus species and E. coli used to treat skin infections (Abedon et al. 2011). Pyophage was 
first developed in 1930‘s  and is today one of the main commercial products of  Georgian 
Eliava Institute of Bacteriophage, Microbiology and Virology (Villarroel et al. 2017). 
Successful phage therapy in treating Netherton syndrome (NS) was reported recently 















immune system with an incidence of 1/200,000 per head of population (Tran and Cohen 
2012; Boskabadi, Maamouri and Mafinejad 2013). In most cases it presents as a triad of 
characteristics including congenital ichthyosiform erythroderma (inflamed red scaling and 
peeling skin), trichorrhexis invaginate (bamboo hair due to hair shaft abnormality), and atopic 
diathesis (predisposition to allergies) which is linked to recurring bacterial infections. NS has 
been linked to the genetic mutations in the serine protease inhibitor of Kazal type 5 (SPINK5) 
gene in the host, which plays a role in regulating skin barrier growth (Leung, Barankin and 
Leong 2018). Zhvania et al., 2017 described the case of a 16-year-old male with NS 
experiencing repeated serious staphylococcal infections. Due to atopic diathesis he was 
allergic to many antibiotics and so phage therapy was attempted at Eliava Phage Therapy 
Centre. Significant improvement in his symptoms was reported within a week after treatment 
with  a cocktail of anti-staphylococcal phage and this improvement continued during the six 
months of continued phage therapy at home. 
C. acnes is an anaerobic bacterium found in the pilosebaceous unit of human skin. C. acnes is 
a dominant commensal skin bacterium and is thought to be a major contributing factor in  
skin disease acne vulgaris. Marinelli, Fitz-Gibbon and Hayes, 2012 isolated 11 C. acnes 
phage from the skin of a diverse group of people ranging in age, geographical location, 
healthy and acne skin. They found that the phage had a broad killing range against different 
P. acne strains. Genome sequencing revealed that the genome diversity of the phage was 
quite small when compared to other phage and they hypothesised that this was due to the 
restricted lipid rich anaerobic environment that it resides in concluding that phage therapy is 
very suitable candidate as a potential antimicrobial treatment for acne.  Studies have 
described isolation of C. acnes phage and the ability of this phage to kill C. acnes (Liu et al. 















acne patients is yet to be completed (Jończyk-Matysiak et al. 2017; Castillo, Nanda and Keri 
2019). 
In the Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Wroclaw, 
Poland, Międzybrodzki et al., (2012) carried out phage therapy on 153 patients and found 
that phage therapy was effective in treating skin, orthopaedic, urinary and respiratory tract 
infections that were resistant to antibiotics. Anti-staphylococcal phages were used in 
treatment of these infections and while the study was performed without a control group, 
36.7% of subjects reported improvements after phage therapy. It was also reported that 
topical application of staphylococcal phage was more effective than other types of phage 
treatment; 16.7% of patients with skin infections improved after topical phage therapy. 
Further studies should be carried out to validate the effectiveness of phage therapy as a 
treatment for skin infections. 
 
Biological tools to treat skin disease indirect - via gut 
Probiotics, Prebiotics, and the Gut-Skin axis 
In 2001, the World Health Organisation (WHO) and the Food and Drug 
Administration(FDA) defined probiotics as ‗live microorganisms which, when administered 
in adequate amounts, confer a health benefit to the host;‘‘ a definition that was revisited and 
clarified by Hill et al., 2015. However, we now know that dead microorganisms can also 
confer health benefits, as aforementioned in this review a heat-treated derivative of Lb. 
johnsonii was effective in treating AD (Blanchet-Réthoré et al. 2017). Many studies have 
shown that ingestion of probiotics influences the gut, which in turn influences the skin 
microbiota, further suggesting the presence of a gut-skin axis. Indeed, Levkovich et al., 2013 















their bodies via changes in skin features. The probiotic initiated an interleukin-10 dependent 
mechanism, which resulted in mice exhibiting increased dermal thickness and shinier fur.  
After consuming the probiotic yogurt, the fitness and fertility of the mice had improved, with 
researchers noting an overall ‗glow of health‘. Rosenfeldt et al., (2003) carried out a study on 
43 children with AD, average age 5.2 years, and showed that ingestion of combination 
probiotic of Lactobacillus rhamnosus 19070-2 and Lactobacillus reuteri DSM 122460 
improved symptoms of eczema. Rosenfeldt et al., continued this study and demonstrated that 
the same probiotic combination alleviates both small intestine permeability and 
gastrointestinal symptoms (Rosenfeldt et al. 2004). Kim et al. show how administration of a 
probiotic cocktail of Bifidobacterium bifidum, Bifidobacterium lactis, Lactobacillus 
acidophilus to pregnant women can confer a protective effect against development of eczema 
in high risk infants in their first year of life. They conducted a study where 112 pregnant 
women with a family history of allergy disorders were divided into two groups: one group 
given a probiotic mix and the other given a placebo. The incidence of eczema was 
significantly lower among  infants whose mothers took the probiotic mix compared to 
mothers who took the placebo however exposure to common food allergens did not result in 
differences in IgE levels (Kim et al., 2010). 
A prebiotic on the other hand is currently defined as ‗a substrate that is selectively utilized by 
host microorganisms conferring a health benefit‘ (Gibson et al., 2017). Prebiotics are 
indigestible oligosaccharides that promote beneficial bacteria to colonise the gut (Ashwini et 
al. 2019). Bateni et al., 2013 demonstrated how Konjac Glucomannan Hydrolysates (GMH), 
a prebiotic, could be used as a novel topical therapy. Twenty-six females with acne lesions 
between the ages of 18-39 were treated with either generic antibiotic or a topical prebiotic 
spray of GMH, both treatments significantly ameliorated in skin health. Contact 















(ACD) (Mowad et al. 2016). Watanabe et al., (2008) demonstrated that ingestion of the 
prebiotic fructo-oligosaccharide (FOS) increased the numbers of intestinal Bifidobacteria 
pseudolongum which  in turn reduced ear swelling (CHS), that was induced by 2,4-
dinitrofluorobenzenein mice.  
 
Other examples of biotherapeutic potential of skin commensals 
Anti-skin cancer   
It has been recently reported that some strains of the human commensal S. epidermidis 
produce a molecule that inhibits DNA polymerase, called 6-N-hydroxyaminopurine (6-HAP), 
and  can protect against skin neoplasia. Nakatsuji et al., 2018 demonstrated that by injecting 
mice with 6-HAP, the growth of melanoma was stopped. They also showed that mice 
colonised with 6-HAP producing S. epidermidis strains did not develop as many tumours as 
mice colonised with a non-6-HAP producing control strain, when exposed to ultra-violet 
radiation. No evidence suggesting damage to either keratinocytes or system toxicity by 6-




 Zipperer et al., 2016 discovered a new ‗‘thiazolidine-containing cyclic peptide‘‘ antibiotic 
‗lugdunin‘ produced by human commensal S. lugdunensis, isolated from the nose of human 
subjects, that inhibited growth and establishment of S. aureus. Lugdunin also displayed 
inhibitory activity against other major pathogens including some streptococci, enterococci, 
















Probiotics in wound healing 
Pseudomonas aeruginosa is a Gram-negative bacterium that has many associations with the 
pathogenesis of cystic fibrosis (Davies 2002), it is however also implicated in burn-wound 
sepsis (Kim et al. 2015). Argenta et al., (2016) created a burn-sepsis mouse model 
incorporating P. aeruginosa and demonstrated that application of probiotic bacteria 
Lactobacillus plantarum to the burn greatly reduced mortality rates of mice when compared 
to untreated model- 90% as opposed to 10%. This suggests an approach to treating wounds 
without use of antibiotics. Recently Li et al., 2019 presented a potential candidate, a strain of 
S. epidermidis for future wound treatment. They demonstrated in vivo how S. epidermidis 
modulated skin inflammation by producing Lipopeptide 78 (LP78), which in turn inhibited 
TLR3-mediated inflammation, promoting wound healing. 
 
Conclusion 
While the extent of the role human skin commensals play in skin health and disease remains 
to be fully understood, it is apparent that like the gut, diversity and balance of bacterial 
communities is vital for skin health. It‘s clear that our skin‘s residents‘ function in many 
ways and there is a wide variety of biological tools with the capability of manipulating the 
skin microbiota in play. Understanding how cutaneous microbiota modulate skin disorders is 
key to developing novel skin therapeutics (Paller et al. 2019; Sun et al. 2019). The global 
emergence of antimicrobial resistance (AMR) is posing a threat to human health (WHO 
Global antimicrobial resistance surveillance system report: early implementation 2017-2018), 
and therefore more attention is being paid to novel alternative therapies with potential to 















essential to further develop these biological tools into therapeutic products for the treatment 
of skin related and other diseases. However, before these tools will be fully exploited there 
are many areas that will require further studies including evaluating potential associations of 
skin microbiota with health and disease using molecular approaches, and elucidation of 
mechanisms of action to tease out signalling pathways. What role does the brain play in 
signalling from gut to skin? Larger in vivo based human trials are required to determine 
whether biological tools such as probiotics, prebiotics, bacteriocins and phage can be used as  
primary prevention or treatment options for skin diseases. 
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